Demonstration of two group-specific TSTAs in adenovirus-induced tumors.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 4319232)

Published in Int J Cancer on July 15, 1970

Authors

J Ankerst, H O Sjögren

Articles by these authors

Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38

Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer (1971) 3.06

Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer (1971) 2.88

A rountine diagnostic test for IgA and IgM antibodies to rubella virus: absorption of IgG with Staphylococcus aureus. J Infect Dis (1974) 2.67

Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol (1989) 2.32

Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J Immunol (1988) 2.28

Transplantation methods as a tool for detection of tumor-specific antigens. Prog Exp Tumor Res (1965) 1.85

Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer (1972) 1.76

After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy (2009) 1.74

Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol (1990) 1.51

Kinetics of IL-2 and interferon-gamma production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to staphylococcal enterotoxin A. Cell Immunol (1985) 1.41

Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer (2000) 1.36

Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol (1988) 1.35

Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer (1973) 1.30

A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol (1991) 1.29

Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity. Int J Cancer (1971) 1.27

Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med (2000) 1.24

Cross-reacting tumor-associated antigen (s) among chemically induced rat colon carcinomas. Cancer Res (1974) 1.24

Demonstration of H-2 isoantigens and polyoma specific tumor antigens by measuring colony formation in vitro. Exp Cell Res (1965) 1.23

Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol (1992) 1.17

Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation. J Immunol Methods (1989) 1.14

Cloning and functional characterization of a subunit of the transporter associated with antigen processing. Proc Natl Acad Sci U S A (1997) 1.09

Sequential studies of serum blocking activity in rats bearing chemically induced primary bowel tumors. J Natl Cancer Inst (1975) 1.08

T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol (1995) 1.07

Effects of BCG on various facets of the immune response against polyoma tumors in rats. Int J Cancer (1973) 1.06

Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cells. Cell Immunol (1991) 1.05

A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med (1993) 1.04

Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol (2001) 1.04

Induction of polyoma specific transplantation antigenicity in Moloney leukemia cells. Exp Cell Res (1965) 1.04

Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy (2006) 1.04

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy (2007) 1.02

Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas. Cell Immunol (1970) 1.02

The Y chromosome: a graveyard for endogenous retroviruses. Gene (1995) 1.02

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy (2009) 1.00

Counteractions of the blocking of cell-mediated tumor immunity by inoculation of unblocking sera and splenectomy: immunotherapeutic effects on primary polyoma tumors in rats. Int J Cancer (1972) 0.99

Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol (1996) 0.99

Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation. Scand J Immunol (1990) 0.98

Demonstration and identification of cytotoxic antibodies and antibodies blocking the cell-mediated antitumor immunity against adenovirus type 12-induced tumors. Cancer Res (1971) 0.98

Specific transplantation antigens of mouse sarcomas induced by adenovirus type 12. J Exp Med (1967) 0.98

"Unblocking" serum activity in vitro in the polyoma system may correlate with antitumour effects of antiserum in vivo. Nat New Biol (1971) 0.98

Monoclonal antibodies produced by immunization with neoglycoproteins containing Gal alpha 1-4Gal beta 1-4Glc beta-O and Gal alpha 1-4Gal beta 1-4GlcNAc beta-O residues: useful immunochemical and cytochemical reagents for blood group P antigens and a differentiation marker in Burkitt lymphoma and other B-cell malignancies. Int J Cancer (1988) 0.95

Induction of mammary fibroadenomas in rats by adenovirus type 9. Int J Cancer (1974) 0.95

Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol (1988) 0.95

Use of a monoclonal rat anti-mouse Ig light chain (RAMOL-1) antibody reduces background binding in immunohistochemical and fluorescent antibody analysis. J Histochem Cytochem (1989) 0.94

Cell-mediated immunity and blocking serum activity to tolerated allografts in rats. J Exp Med (1973) 0.94

The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets. Scand J Immunol (1992) 0.94

In vitro demonstration of humoral and cell-bound immunity against common specific transplantation atigen(s) of adenovirus 12-induced mouse and hamster tumors. J Exp Med (1967) 0.93

Effect of BCG and allogeneic tumor cells on adenovirus type 12 tumorigenesis in mice. Nature (1969) 0.93

Antigen-independent binding of rat immunoglobulins in a radioimmunoassay. Solutions to an unusual background problem. J Immunol Methods (1984) 0.93

Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. J Neuroimmunol (1993) 0.91

Fluorescence studies of hematoporphyrin derivative in normal and malignant rat tissue. Cancer Res (1986) 0.91

Rapid response to Con A by CD4+CD45R- rat memory lymphocytes as compared to CD4+CD45R+ lymphocytes. Cell Immunol (1989) 0.89

Biological characterization of structural components of Adenovirus type 12. J Gen Virol (1969) 0.88

The immunology of large bowel carcinoma in a rat model. Cancer (1975) 0.88

Destruction of cultivated melanoma cells by lymphocytes from healthy Black (North American Negro) donors. Int J Cancer (1973) 0.88

Staphylococcal protein A (SpA) does not induce production of interferon-gamma in human mononuclear blood cells. Cell Immunol (1984) 0.88

Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine. Int J Cancer (1983) 0.87

Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol (2000) 0.87

Facilitation of polyoma tumor growth in rats by blocking sera and tumor eluate. Int J Cancer (1972) 0.86

Monocyte-regulated IFN-gamma production in human T cells involves CD2 signaling. J Immunol (1993) 0.86

Non-specific steroidal esterase activity and distribution in human and other mammalian tissues. Clin Chim Acta (1994) 0.86

Polymorphism of normal factor IX detected by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1985) 0.86

An antigen present in rat adenocarcinoma and normal colon non-epithelial stroma is a novel Forssman-like glycolipid based on isoglobotetraosylceramide. Biochim Biophys Acta (1986) 0.86

Cytotoxicity of adenovirus-antibody aggregates: sensitivity to different cell strains, and inhibition by hexon antiserum and by complement. J Virol (1973) 0.86

Costimulation of human CD4+ T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles. J Immunol (1994) 0.85

Laser-induced fluorescence in malignant and normal tissue of rats injected with benzoporphyrin derivative. Photochem Photobiol (1993) 0.85

Induction of transplantation immunity to rat colon carcinoma isografts by implantation of intact fetal colon tissue. Int J Cancer (1980) 0.84

Computerized image analysis as a tool to quantify infiltrating leukocytes: a comparison between high- and low-magnification images. J Histochem Cytochem (2001) 0.84

In vivo induction of gamma/delta T cells with highly potent and selective anti-tumor cytotoxicity. Eur J Immunol (1991) 0.84

Association of decreased phosphorylation of ERK-2 with costimulation of rat T cell activation by MEK-1 inhibitors and TGF-beta1. Immunol Lett (2000) 0.84

Isograft resistance to Rous sarcomas in mice inoculated with Rous chicken sarcoma when newborn. Exp Cell Res (1965) 0.84

Abrogation of staphylococcal enterotoxin A-induced suppressor cell activity by the anti-Tac monoclonal antibody. Scand J Immunol (1987) 0.83

Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing. J Biol Chem (1999) 0.83

Cross-reacting TSTAs in adeno 7 and 12 tumors demonstrated by 51Cr-cytotoxicity and isograft rejection tests. Int J Cancer (1969) 0.83

Independent regulation of IFN-gamma and tumor necrosis factor by IL-1 in human T helper cells. J Immunol (1990) 0.83

Histamine modulates the production of interferon-gamma and interleukin-2 by mitogen-activated human mononuclear blood cells. Cell Immunol (1985) 0.83

Tapasin is required for efficient peptide binding to transporter associated with antigen processing. J Biol Chem (2000) 0.83

Fractionation of rat IgG subclasses and screening for IgG Fc-binding to bacteria. Mol Immunol (1982) 0.83

Histamine acts directly on human T cells to inhibit interleukin-2 and interferon-gamma production. Cell Immunol (1987) 0.83

Separation of rat leukocytes by countercurrent distribution in aqueous two-phase systems. II. Subpopulations which mediate selective and nonselective lysis of normal and colon carcinoma target cells in vitro. Cell Immunol (1978) 0.83

Histamine inhibits interferon-gamma production via suppression of interleukin 2 synthesis. Cell Immunol (1986) 0.83

Studies on adenovirus type 9-induced mammary fibroadenomas in rats and their malignant transformation. Cancer (1977) 0.83

Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA). Acta Oncol (1993) 0.82

Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. Respir Med (2001) 0.82

Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy (2005) 0.82

Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol Immunother (1993) 0.82

Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol Immunother (2001) 0.82

Cloning of human hybridoma, myeloma and lymphoma cell lines using enriched human monocytes as feeder layer. J Immunol Methods (1983) 0.81

The three isoforms of transforming growth factor-beta co-stimulate rat T cells and inhibit lymphocyte apoptosis. Scand J Immunol (1998) 0.81

Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther (1999) 0.81

Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Gene Ther (2000) 0.81

Tumor-specific immunity in the course of primary polyoma and Rous tumor development in intact and immunosuppressed rats. Cancer Res (1971) 0.81

The use of monoclonal antibodies in measuring factor VIII/von Willebrand factor. Scand J Clin Lab Invest (1985) 0.81

Hyperhomocysteinemia and changed plasma thiol redox status in chronic obstructive pulmonary disease. Clin Chem Lab Med (2001) 0.81

Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules. Scand J Immunol (1993) 0.81

Inhibition of antibody binding to viable cells by liposomes containing purified rat spleen glycoprotein. J Immunol Methods (1983) 0.81